Abstract
BRAF V600E and microsatellite instability (MSI) are two key biomarkers in metastatic colorectal cancer (mCRC). Around 30% of patients who harbor a BRAF V600E mutation are found to be MSI-high (MSI-H). Using real-world-data, this study compared overall survival (OS) by BRAF V600E status and further stratified by MSI status.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
